The research demonstrated that bariatric surgery produces better weight loss results at lower maintenance expenses than GLP 1 medication therapy which demands continuous administration
Elderly Patients: No dose adjustment is required based on age alone
A review of 10 clinical studies found that caloric intake is reduced by 16 to 39 percent in adults treated with a GLP-1 receptor agonist or GIP/GLP-1 receptor agonist [1], and this may result in a reduced intake of protein, micronutrients, fiber, and fluids
A patients BMI determines their eligibility for GLP-1s, and those cut-offs come from clinical trials: BMI of 27 for patients with comorbidities and BMI of 30 for those without
For micro-dosing within the Wolverine Stack framework, consider BPC-157 at 0.1 to 0.15 mg daily combined with Tb-500 at 2 mg once or twice weekly
Injectable semaglutide (Ozempic) reduces HbA1c levels by 1.4%1.6% at week 30, again depending on the dosage strength